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Abstract
Current treatments available for African sleeping sickness or human African trypanosomia-
sis (HAT) are limited, with poor efficacy and unacceptable safety profiles. Here, we report a
new approach to address treatment of this disease based on the use of compounds that
bind to parasite surface glycans leading to rapid killing of trypanosomes. Pradimicin and its
derivatives are non-peptidic carbohydrate-binding agents that adhere to the carbohydrate
moiety of the parasite surface glycoproteins inducing parasite lysis in vitro. Notably, pradi-
micin S has good pharmaceutical properties and enables cure of an acute form of the dis-
ease in mice. By inducing resistance in vitro we have established that the composition of
the sugars attached to the variant surface glycoproteins are critical to the mode of action of
pradimicins and play an important role in infectivity. The compounds identified represent a
novel approach to develop drugs to treat HAT.
Author Summary
Trypanosoma brucei, the causative agent of African trypanosomiasis, is coated with a
dense layer of the variant surface glycoprotein (VSG), which plays an essential role in anti-
genic variation and the ability of the parasite to evade the immune system. VSGs are N-
glycosylated with complex and/or mannose-richN-glycans by two oligosaccharyltransfer-
ase activities in a site-specificmanner. Here, we describe that a series of non-peptidic car-
bohydrate binding agents, previously reported to display antifungal and antiviral
properties, exhibit a marked trypanocidal activity. Pradimicin A (PRM-A) and pradimicin
S (PRM-S) show specific binding to VSGs and a pronounced cytocidal effect by inducing
defects in endocytosis and cytokinesis. Remarkably, PRM-S produces parasitological cure
in two different models of acute sleeping sickness. Information on the mode of action was
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provided by generating PRM-A-resistant parasites, which suffered from defective glycan
composition as a consequence of down-regulation of oligosaccharyltransferasegenes.
Aberrant glycosylation of VSGs resulted in decreased binding of pradimicins but reduced
parasite infectivity underscoring the role of glycosylation in virulence.Our findings iden-
tify antibiotics with the ability to effectively bind to glycans of the parasite surface as agents
capable of affording parasitological cure, thereby providing a novel avenue for design of
highly specific drugs to combat African trypanosomiasis.
Introduction
Human African trypanosomiasis or sleeping sickness is a neglected disease caused by the pro-
tozoan parasite Trypanosoma brucei. Treatments are largely insufficient and unsatisfactory and
new approaches for drug design are highly necessary.
T. brucei parasites living in the mammalian host rely on antigenic variation to evade the
immune system of the host. They are mainly covered by only one kind of a variant surface gly-
coprotein (VSG) that constitutes an effective barrier that protects from effectors of the host
immune system. In the formation of this protective barrier theN-glycosylation of VSGs is of
major importance [1]. The VSGs are covered by mannose-rich and complex glycans [2–4].
During antigenic variation this shield is changed by expressing new VSGs in a stochastic pro-
cess known as VSG switching.
Recently, we have reported a series of carbohydrate-binding agents (CBAs) that bind to par-
asite surface glycoproteins and exhibit a strong trypanocidal activity against the clinically rele-
vant bloodstream form, presenting activity in the nanomolar range [5]. Analysis of the mode of
action showed a rapid internalization of glycoprotein-CBA complexes and accumulation in the
lysosome leading to perturbation of endocytosis and progression of the cell cycle. Selection for
CBA resistance resulted in modification of theN-glycan composition of VSGs by changes in
the expression of oligosacharyltransferases.Thus, CBAs appear to exert their mode of action
against Trypanosoma by specifically binding to surface glycans [5, 6].
However, the previously reported antitrypanosomal CBAs were proteins with molecular
masses ranging between 8,700 Da (i.e., UDA) and 50,000 Da (i.e., HHA, GNA) or even higher.
Proteins present a series of disadvantages to become potential drugs, including efficient scale-
up, poor, if any, oral bioavailability and/or potential generation of an immune response.
Non-peptidic, low-molecular-weight antibiotics designated PRM-A and benanomycin A
have been discovered in the culture fluid of Actinomadura hibisca [7] and Actinomadura sp
[8], respectively. PRM-A inhibits the growth of fungi (such as Aspergillus) [9] and viral infec-
tions [10]. It has been shown that PRM-A acts as a lectin in terms of glycan recognition, antivi-
ral activity, and drug resistance patterns [11]. Members of the pradimicin family are unique
among natural products in their ability to specifically bind sugars in a Ca2+-dependent manner
[9]. PRM-S is a highly water-soluble, negatively charged derivative of the antibiotic PRM-A in
which the terminal xylose moiety has been replaced by 3-sulfated glucose. The antibiotic is
nontoxic against a variety of cell lines, is not mitogenic, and does not induce cytokines or che-
mokines in peripheral bloodmononuclear cell cultures [12]. In addition, pradimicins can be
modified chemically, such as BMY28864 which is a derivative of PRM-A. PRM-A and PRM-S
exhibit activity against fungi, yeasts and several viruses including HIV and HCV [9, 11–13],
while the derivatives PRM-FS [14], PRM-FA-1 [15], BMS181184 [16] and BMY28864 [17]
were reported to exhibit efficient antifungal activity.
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Here we report that pradimicins inhibit the growth of T. brucei bloodstream forms at low
micromolar concentrations by perturbing cytokinesis and endocytosis and consequently
inducing parasite cell lysis. We provide information on their mode of action by generating
mutant parasite cells resistant to the drug and examining binding efficiencyof the pradimicins
to parental and resistant parasitic VSGs and the glycan composition. Furthermore, we found
that treatment at 50 mg/kg with PRM-S cures T. brucei brucei and T. brucei rhodesiense infec-
tion in mice.We propose that pradimicins and carbohydrate-binding agents in general may
provide a unique and highly novel avenue for the development of an efficient treatment of par-
asitic diseases.
Results
Pradimicins exhibit in vitro trypanocidal activity
The in vitro trypanocidal activities of PRM-A, PRM-S and the derivatives BMY28864,
PRM-FS, PRM-FA-1 and BMS181184 were evaluated against the bloodstream forms of T. bru-
cei. All of them exhibited 50% effective concentration (EC50) values in the low micromolar
range (Figs 1 and S1, Table 1). PRM-A and PRM-S that preferentially exhibit binding specific-
ity for α(1,2) mannose residues were the most active.
A more detailed study of the effect of pradimicins on growth and morphologywas accom-
plished. Thus, a time course of the consequences of exposure to 1-, 5-, 10- and 20-fold the EC50
was performed. Parasite viability was severely compromised at the different concentrations
tested and total lysis was observed at 10- and 20-fold the EC50 after 4 to 8 h of treatment (Fig
2A and 2B). To determine cytocidal activity, PRM-S was removed after 8 h of exposure at dif-
ferent concentrations and growth was monitored thereafter. PRM-S behaved as a trypanocidal
agent at concentrations 10-fold the EC50 since complete abolishment of growth was achieved
at this and higher concentrations (Fig 2C). Furthermore, after 1 h of incubation with PRM-S at
53.0 μM, cells exhibited a rounded shape and detachment of the flagellum (Fig 2D). In order to
identify cell cycle alterations, the distribution of nuclei and kinetoplasts by DAPI staining was
examined after PRM-S exposure at 5.3 μM (EC50) for 48 h (Fig 2E and 2F). The microscopic
analysis revealed a slight increase of cells which have completed mitosis (2N2K) (17%), as well
as the emergence of a population with multiple nuclei and kinetoplasts (XNXK) (11.5%) sug-
gesting that PRM-S impairs cytokinesis by binding to the variant surface glycans.
PRM-S binds to the VSGs of the trypanosome surface leading to
endocytosis defects
As a first approach for assessing effective pradimicin binding to glycans of the surface glyco-
proteins, competition assays were performed between PRM-S and HHA, a lectin that has been
previously reported to bind VSGs [5], and PRM-S and CV-N, a lectin with a similar α(1,2)
Man specificity as PRM-S. Accordingly, different PRM-S concentrations were examined first
in the presence of HHA-FITC conjugates and fluorescencewas analysed at 0 min and 60 min
of incubation by flow cytometry and microscopy. HHA binding to the surface coat (deter-
mined at 0 min) was significantly decreased by 1.7 and 3-fold after incubation with 25 μg/ml
and 50 μg/ml PRM-S, respectively (Fig 3A) and uptake was drastically reduced at the highest
concentration tested compared to the control without PRM-S (Fig 3A and 3B). We also moni-
tored fluid-phase endocytosis (dextran uptake) in the presence and absence of PRM-S and
HHA in order to discard possible effects of HHA on endocytosis that could be interpreted as a
decrease in binding/uptake of PRM-S. Fig 3C shows that while PRM-S produces a significant
reduction in dextran internalization at 25 to 50 μg/ml in the absence of additional HHA, HHA
Pradimicins Induce Cure in Animal Models of Sleeping Sickness
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Fig 1. Structural formulae of the pradimicins.
doi:10.1371/journal.ppat.1005851.g001
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at 1 μg/ml does not affect endocytosis at the PRM-S concentrations tested (Fig 3D). In the case
of competition assays with CV-N-FITC conjugates, fluorescencewas analysed at 0, 10 and 60
min of incubation by flow cytometry and microscopy. The presence of 25 μg/ml PRM-S
reduced CV-N binding to the surface coat at 0 and 60 min of incubation to 59% and 64% of the
control values respectively (Fig 3E and 3F). Therefore, we conclude by these observations that
PRM-S binds to glycans of the trypanosome surface glycoproteins, such as the VSGs, in a simi-
lar fashion to HHA and CV-N and subsequently, the PRM-S-VSGs complex triggers endocyto-
sis defects and parasite death.
Selection in vitro of PRM-A-resistant parasites
PRM-A-resistant parasites were generated in order to provide an insight into the mode of
action. Adaption of the parasites to this CBA was achieved by exposure to stepwise increasing
concentrations of PRM-A and cell lines named PRM-A25, PRM-A50 and PRM-A100 were
generated that grew and were isolated at concentrations of 25, 50 and 100 μg/ml PRM-A,
respectively (corresponding to 8-, 16- and 32-fold the EC50 value for the parental cell line). The
resistance selectivity index (ratio EC50 resistant parasite/EC50 parental parasite) was deter-
mined as an estimate of the degree of drug resistance. A value of 25 was obtained for PRM-A25
and PRM-A50, and of 40 for PRM-A100 (Table 2). The drug-resistance phenotype was
retained after 3 months in the absence of PRM-A pressure suggesting that we are dealing with
a stable and genetically-encodedphenotype.
Cross-resistance was analysed for the PRM-A100 cell line using a variety of CBAs with pre-
dominant different specificities;HHA (α(1,3)-α(1,6)Man), EHA (Man), GNA (α(1,3) Man),
NPA (α(1,6) Man), UDA (GlcNAc oligomers) and PRM-S (α(1,2) Man) were tested. Cross-
resistance indices (R-index) were calculated as ratios of EC50 PRM-A100 /EC50 parental cell
line (BSF). PRM-A100 cells exhibited significant resistance to PRM-S, HHA and EHA and low
resistance to UDA, NPA and GNA (Table 3).
PRM-A exposure to T. brucei causes changes in VSG N-glycosylation
We have reported previously that prolonged exposure to peptidic CBAs lead to induction of
CBA resistance caused by genotypic changes in theN-glycosylation profile [5, 6]. In order to
evaluate whether the non-peptidic CBAs would produce a similar phenotype, the expression of
VSGs and theirN-glycosylation nature were analysed in parasites resistant to PRM-A. First,
indirect immunofluorescence using an anti-TbVSG221 polyclonal antibody [18] revealed that
VSG221 expression was maintained in all PRM-A-resistant cells (Fig 4A). Secondly, the soluble
form of VSG (sVSG) was isolated and resolved using SDS/PAGE and Coomassie Blue staining.
Unlike parental cells, sVSGs of all PRM-A-resistant cells appeared as doublets, which were pos-
itively identified as VSG221 by tryptic peptidemass fingerprinting using MALDI-TOF analysis
(Voyager DE PRO, AB Sciex). The existence of two forms of sVSG with different migration
Table 1. EC50 values of non-peptidic CBAs tested against T. brucei BSFs.
CBA Specificity EC50 (μg/ml) EC50 (μM)
PRM-A α (1,2) Man 3.20 ± 0.04 3.80 ± 0.05
PRM-S α (1,2) Man 5.85 ± 0.08 6.44 ± 0.08
PRM-FS D-mannoside 13.0 ± 0.7 13.5 ± 0.8
PRM-FA1-mono sugar D-mannoside 24.3 ± 2.1 33.3 ± 2.8
BMS181184 D-mannoside 17.1 ± 1.0 20.3 ± 1.2
BMY28864 D-mannoside 18.4 ± 2.4 21.1 ± 2.8
doi:10.1371/journal.ppat.1005851.t001
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Fig 2. Effect of PRM-S treatment on in vitro T. brucei BSFs. (A) Plot showing the number of parasites in culture exposed to
increasing concentrations of PRM-S (5.3, 26.3, 53.0 and 106.0 μM that correspond to 1-, 5-, 10- and 20-fold the EC50,
respectively). (B) Plot of the percentage of lysed parasites after PRM-S treatment for 8 h. (C) Accumulated growth after drug
removal of parasites treated with PRM-S for 8 h. (D) Microscopy images of cultured samples after exposure to PRM-S for 1 h.
Cells were stained with DAPI and Giemsa and observed by fluorescence and light microscopy. (E) Nuclei (N) and kinetoplasts
(K) of parasites treated with 5.3 μM for 48 h were stained with DAPI and categorized according to the number of nuclei and
kinetoplasts: 1N1K, 1N2K, 2N2K and XNXK. (F) Microscopy images illustrating DIC, DAPI and Giemsa staining of cells
exposed to 5.3 μM PRM-S for 48 h. The asterisk shows significant differences calculated by the Student’s t-test (n = 2). *,
p < 0.05. Bars, 10 μm.
doi:10.1371/journal.ppat.1005851.g002
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Fig 3. PRM-S binding and fluid-phase endocytosis analysis. PRM-S binding to parasite surface VSGs was
evaluated by competition labelling assays using HHA, a lectin that binds to VSGs and is rapidly endocytosed [5]
or CV-N, a lectin that binds to the surface coat of the trypanosomes. Labelling was measured by FACS at 0 min,
10 min and 60 min of incubation at increasing PRM-S concentrations and visualized by 3D microscopy. (A and B)
Quantification (A) and images (B) of the labelling with HHA-FITC (1 μg/ml) in the presence of PRM-S. (C and D)
Fluid-phase endocytosis analysis using Alexa Fluor 488-labelled dextran 10,000 in the absence (C) or in the
presence (D) of HHA (1 μg/ml). (E and F) Quantification (E) and images (F) of the labelling with CV-N-FITC
(0.6 μg/ml) in the presence of PRM-S. Bars, 10 μm. The asterisks show significant differences calculated by the
Student’s t-test (n = 3). *, p < 0.05, **, p < 0.005 and ***, p < 0.0005 vs the parental strain.
doi:10.1371/journal.ppat.1005851.g003
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properties (Fig 4B and 4C), in addition to differences in endoglycosidase digestion (Fig 4D),
clearly indicated the induction of modifications in theN-glycan nature of the resistant parasite
strains. Endo H or PNGase F, which remove conventional triantennary oligomannose and
hybridN-glycans or all types of N-glycans respectively, were used to confirm this. Parental
sVSG harbours an Endo H-resistant (Asn263) and an Endo H-sensitive (Asn428) N-glycosyla-
tion site, coming from the action of different oligosaccharyltransferase activities, such as
TbSTT3A and TbSTT3Bwhich transfer Man5GlcNAc2 or mainly Man9GlcNAc2 structures,
respectively [19]. In the case of PRM-A-resistant strains, after Endo H treatment no molecular
mass shift was observed,while PNGase F digestion converted both bands into a fully deglycosy-
lated form (Fig 4D). Therefore, two glycoforms of VSG221 seem to coexist in the resistant pop-
ulation. The VSG221 sequences of PRM-A50 and PRM-A100 strains were identical to that of
the parental T. brucei BSF strain used in this study ruling out the possibility that changes in gly-
cosylation are due to mutations in theN-glycosylation sites (S2 Fig).
Blotting with lectins of different specificitieswas performed to further characterize the
nature of theN-glycans. We used the TL lectin that recognizes poly-N-acetyl lactosamine [21]
or the Manβ1-4GlcNAcβ1-4GlcNAc trisaccharide core of paucimannose glycans [22], ECL dis-
playing preference for single LacNAc units [23] but also with any poly-N-acetyl lactosamine-
containing glycoproteins, and ConAwith oligomannose- and hybrid glycans-containing
Manα1-3(Manα1–6)Manα1-specificity [24–26]. In addition, chitin hydrolysate, D-lactose, and
α-methylmannose, which are inhibitors of TL, ECL and ConA, respectively, were included in
the study as specificity controls. Fig 5A shows that the binding of TL or ECL to sVSGs was sig-
nificantly increased in PRM-A100, which further suggests changes in the glycosylation status
from oligomannose to paucimannoseN-glycans containing mainly one or severalN-acetyl
Table 2. EC50 values for parental (BSF) and PRM-A-resistant T. brucei cell lines. Resistance indices
(R-index) for PRM-A-resistant cells with respect to the parental strain are indicated.
Cell line EC50 (μg/ml) EC50 (μM) R-indexa
Tb BSF 3.2 ± 0.1 3.8 ± 0.05 1.0
PRM-A25 82 ± 4 98 ± 4 25.8
PRM-A50 86 ± 2 103 ± 3 27.1
PRM-A100 127 ± 7 152 ± 8 40.0
PRM-A50 p-Rem (3M)b 95 ± 12 113 ± 15 29.7
PRM-A100 p-Rem (3M)b 126 ± 5 150 ± 6 39.6
aResistance selectivity index or ratio EC50 PRM-A-resistant cells/EC50 parental cells.
bPost-removal time period of cell culture in the absence of PRM-A is indicated between parentheses.
doi:10.1371/journal.ppat.1005851.t002
Table 3. EC50 values and cross-resistance (R) indices of PRM-A100 and parental cell lines.
CBAs Specificity EC50 Tb BSF (μM) EC50 PRM-A100 (μM) R-indexa
HHA α(1,3)- α(1,6) Man 0.020 ± 0.001 0.23 ± 0.03 11.5
EHA Man 0.014 ± 0.0003 0.17 ± 0.02 11.9
GNA α(1,3) Man 0.043 ± 0.002 0.19 ± 0.01 4.5
NPA α(1,6) Man 0.058 ± 0.001 0.29 ± 0.008 5.0
UDA GlcNAc oligomers 0.225 ± 0.006 1.7 ± 0.002 7.4
PRM-S α(1,2) Man 6.4 ± 0.1 77.7 ± 0.8 12.1
aResistance selectivity index or ratio EC50 PRM-A100-resistant cells/EC50 parental cells.
doi:10.1371/journal.ppat.1005851.t003
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lactosamine structures. However, the additional presence of any abbreviated core structures
derived from paucimannoseN-glycans cannot be discarded. In contrast, the binding of ConA
to sVSG was unaltered in the PRM-A-resistant cells. When whole cell extracts were probed
with TL, ECL and ConA,moderate changes in the glycosylation patterns were observed.
Changes inN-glycosylation were also assessed by labelling with lectin-FITC conjugates with
different glycan binding specificities:CV-N-FITC (α(1,2) Man), HHA-FITC (α(1,3)- α(1,6)
Man) and UDA-FITC (GlcNAc oligomers). Thus, resistant cells had a strongly reduced ability
to bind to all of the lectins tested, CV-N (Fig 5B and 5E), HHA (Fig 5C and 5F) and UDA (Fig
5D and 5G), even after culture for 3 months in the absence of PRM-A.
Fig 4. Analysis of the nature and N-glycosylation status of the VSG expressed in PRM-A-resistant trypanosomes. (A)
Indirect immunofluorescence microscopy analysis of VSG221 expression in parasites resistant to PRM-A probed with a polyclonal
antibody against VSG221. Nuclear and kinetoplast DNA was stained with DAPI. Bars, 10 μm. (B) sVSGs of parental and resistant
strains were purified as described [20] and analysed by SDS/PAGE and Coomassie blue staining. (C) Western-blot analysis of
sVSG isolated from parental and PRM-A100 cells using an anti-TbVSG221 polyclonal antibody. (D) Endoglycosidase treatment of
sVSG samples with Endo H (that removes oligomannose N-linked glycans) or PNGase F (that removes all N-linked glycans),
followed by SDS/PAGE and Coomassie blue staining analysis.
doi:10.1371/journal.ppat.1005851.g004
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Fig 5. Assessment of the VSG glycosylation status by lectin blotting and labelling with lectins. (A) sVSG and cell pellets lysates obtained
after hypotonic lysis from parental and PRM-A100 lines were subjected to SDS-PAGE, transferred to a nitrocellulose membrane and probed with
TL, ECL and ConA lectins. Ponceau staining was used as loading control. Addition of chitin hydrolysate (inhibitor), D-lactose and α-methyl
mannose was used as a specificity control for TL, ECL or ConA, respectively. (B-G) Live cells of parental and PRM-A100 lines were labelled with
CV-N-FITC (B and E), HHA-FITC (C and F) or UDA-FITC (D and G) conjugates and fluorescence was quantified by FACS analysis and visualized
Pradimicins Induce Cure in Animal Models of Sleeping Sickness
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For a more detailed view ofN-glycosylation of VSG221 from PRM-A100-resistant parasites,
free and procainamide glycans after enzymatic cleavage with PNGase F were analysed by both
MALDI-TOFMS and (ultra)-high performance liquid chromatography-fluorescence coupled to
mass spectrometry (UPLC-FLD/MS).Assignment of peaks was based on exact mass and previ-
ous biochemical knowledge of the trypanosomeglycome or via diagnostic fragment ions [19].
The twomajor peaks of MALDI-TOF spectra obtained for Tb BSF free glycans atm/z 932.877
and 1905.687, were assigned to paucimannoseMan3GlcNAc2 (H3N2 withm/z 932.877) and tri-
antennary oligomannoseMan9GlcNAc2 (H9N2,m/z 1905.687), respectively. In line with previ-
ously published trypanosomaVSG glycosylation profiles, further peaks were tentatively assigned
to the oligomannoses structures such as the biantennary H4N2 (Man4GlcNAc2,m/z 1095.025)
or the triantennaryH5N2 (Man5GlcNAc2,m/z 1257.171), H6N2 (Man6GlcNAc2,m/z 1419.308),
H7N2 (Man7GlcNAc2,m/z 1581.433) and H8N2 (Man8GlcNAc2,m/z 1743.564). In addition, we
observedpeaks corresponding to the biantennary hybridN-glycans H3N3 (Man3GlcNAc3,m/z
1136.077), H4N3 (Man4GlcNAc3,m/z 1298.221), H5N3 (Man5GlcNAc3,m/z 1460.358) and
H6N3 (GlcMan5GlcNAc3,m/z 1622.476). Further peaks in the glycan profile were assigned to
the poly-N-acetyl lactosamine complex N-glycans Gal2Man3GlcNAc4 (H5N4,m/z 1663.538) and
Gal4Man3GlcNAc6 (H7N6,m/z 2394.116) (S3 Fig). The analysis of glycan compositionmostly
agrees with the results previously obtained by Manthri et al for VSG221 [19].
In the PRM-A100 resistant cell line, the oligomannose structures H3N2, H4N2, H5N2,
H6N2 and H9N2 were found whereas H7N2 and H8N2 were absent. In addition, peaks corre-
sponding to hybridN-glycans (H3N3, H4N3, H5N5 and H6N3) and complex N-glycans
(H5N4 and H7N6) were identified. The two newH4N4 (m/z 1501.401) and H6N5 (m/z
2028.827) species present in the profile were assigned to GalMan3GlcNAc4 and Gal3Man3Glc-
NAc5 structures, respectively (S4 Fig). In-source fragmentation of ions atm/z 1663.538,
2028.827 and 2394.116 produced diagnostic fragments indicating the presence of poly-N-acetyl
lactosamine structures in the H6N5 and H7N6 species and terminalN-acetyl lactosamine in
the H5N4 species (S5–S7 Figs). UPLC-FLD/MS analysis provided a more quantitative view of
the glycan distribution present on Tb BSF VSG221 highlightingH9N2 triantennary oligoman-
nose and H4N2 and H3N2 paucimannose structures as major compounds together with minor
amounts of other triantennary oligomannose, hybrid and complex N-glycans. In contrast,
UPLC-FLD/MS analysis of procainamide labelled glycans from sVSG221 of PRM-A100-resis-
tant parasites presented a ~8-fold decrease in oligomannose structures (H9N2 and H8N2) and
a significant increase in the hybrid (H4N3, H5N3 and H6N3) and complex N-glycans with
poly-N-acetyl lactosamines (H5N4, H6N5 and H7N6), whereas paucimannoside levels (H3N2,
H4N2 and H3N3) remained unaltered (Fig 6 and Table 4). Therefore, these results firmly dem-
onstrate that alterations inN-glycosylation occur in response to PRM-A pressure, leading to an
N-glycan profile with a lower content of oligomannose structures containing α(1,2) or α(1,3)-α
(1,6) bonds and the emergence of complex glycans with terminal poly-N-acetyl lactosamine
motifs, which would be responsible for the decreased binding affinity of pradimicins.
Pradimicins interact directly with parasite VSG221
To confirm that indeed pradimicin interacts with parasite-encodedVSGs, surface plasmon reso-
nance studies (SPR) were performed using VSG221 derived from parental (BSF) and drug
(PRM-A100)-resistant T. brucei cell lines. Both VSGs were immobilized on a sensorchip. Paren-
tal Tb BSF VSG221 was bound at low and high density (826 and 6,500 RU, respectively) and
by 3D microscopy. Bars, 10 μm. The asterisks show significant differences calculated by the Student’s t-test (n = 3). *, p < 0.05, **, p < 0.01 and
***, p < 0.005 vs the parental strain.
doi:10.1371/journal.ppat.1005851.g005
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PRM-A100 VSG221 derived from the drug-resistant parasites at high density (6,070 RU) (Fig
7). PRM-A binding to the low-density wild-typeTb BSF VSG221-based sensorchip was hardly
visible in the sensorgrams. Only 50 μM PRM-A provided a poor binding amplitude (Fig 7A).
Instead, using the high-density parental Tb BSF VSG221 sensorchip, concentration-dependent
binding of PRM-A could be observed (Fig 7B). Interestingly, binding of PRM-A to the high-
density PRM-A100-resistant VSG221-bound sensorchip caused also a concentration-dependent
binding amplitude, but at a ~ 10-fold lower efficiency than to the parental Tb BSF VSG221 that
Fig 6. Analysis of N-glycans from PRM-A100-resistant sVSG221. Integrated UPLC-FLD chromatograms of
procainamide labelled glycans from resistant (PRM-A100) and control (Tb BSF) N-glycan samples labelled with
procainamide.
doi:10.1371/journal.ppat.1005851.g006
Table 4. Relative quantification (% abundance) of N-glycans from control (Tb BSF) and resistant (PRM-A100) cell lines. Data extracted and normal-
ized from UPLC-FLD chromatograms.
Mannosides Tb BSF (%) PRM-A 100 (%) Hybrid N-glycans Tb BSF (%) PRM-A 100 (%) Complex N-glycans Tb BSF (%) PRM-A 100 (%)
H3N2 17.8 22.4 H3N3 5.7 1.2 H4N4 2.4 1.2
H4N2 11.0 10.7 H4N3 5.4 10.9 H5N4 2.8 8.2
H5N2 5.0 2.9 H5N3 3.6 6.5 H6N5 0.5 1.6
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was immobilised at comparable densities (6,070 and 6,500 RU, respectively) (Fig 7C). A similar
phenomenon was observed for the more-soluble PRM-S derivative (Fig 7D–7F). A significant
concentration-dependent binding to the parental Tb BSF VSG221-bound sensorchip was
observedand this binding was much more pronounced for the high-density compared to the
low-density Tb BSF VSG221 sensorchip. As demonstrated for PRM-A, binding of PRM-S to
PRM-A-resistant VSG221 was 6- to 7-fold less pronounced than to the parental VSG221.
Attempts to calculate the binding affinities (KD) of the pradimicins, as previously reported for
HIV gp120 [12], to parental and PRM-A-resistant VSG221, including determination of the kon
and koff rates failed,mainly due to the lack of 1:1 stoichiometric kinetics of the binding. Indeed,
given the small size of the pradimicins, it might be assumed that several pradimicinmolecules
can bind on one single VSG molecule given the high amount of glycans present on VSG. In addi-
tion, the pradimicin antibiotics are known to internally staple (associate) at higher (micromolar)
concentrations, further compromising relevant calculations of the KD values for the parental and
resistant VSGs. Nevertheless, the SPR-based binding study of the pradimicins to parental and
PRM-A-resistant VSG convincingly revealed that PRM-A and PRM-S concentration-depen-
dently bind to VSG and that both PRM-A and PRM-S showed a compromised binding efficiency
for the PRM-A100-resistant versus the parental Tb BSF VSG. These findings confirm the specific
binding of the pradimicins to parasitic VSGs, and the poorer binding of PRM-A and PRM-S to
PRM-A-resistant VSG than parental VSG. In addition, they support our view and provide further
evidence that resistance against pradimicins is due to the glycan changes in the parasitic VSG.
Prolonged PRM-A exposure induces down-regulation of the STT3A and
STT3B genes yielding parasites with reduced infectivity in mice
Obvious candidates potentially involved in the changes in carbohydrate composition are the
oligosaccharyltransferase (OST) activities coded by three genes: STT3A, STT3B and STT3C [5,
Fig 7. Surface plasmon resonance analysis. (A, B and C) SPR analysis of serial dilutions of PRM-A from 1.56 to 50 μM exposed to the
parental Tb BSF VSG221 bound at low density (826 RU) (A) or high density (6,500 RU) (B) and to the PRM-A100-resistant cell line VSG221
bound at high density (6,070 RU) (C) on a CM5 sensor chip. (D, E and F) SPR analysis of serial dilutions of PRM-S using the same conditions as
described above.
doi:10.1371/journal.ppat.1005851.g007
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6]. OSTs mediateN-glycosylation of VSGs in a site specificmanner [19, 27, 28]. Accordingly,
TbSTT3A,TbSTT3B and TbSTT3CmRNA levels were examined by RT-qPCR in the
PRM-A100 cell line. Specific primers designed against the variable region of each gene were
used in the analysis [5]. The occurrence of recombination events between these genes was also
examined using a combination of primers. S7 Fig shows that mutant parasites harbour only
canonical genes. However a reduction in the expression levels of TbSTT3A (2.0-fold) and
TbSTT3B (2.9-fold) in PRM-A-resistant cells compared to the parental line was observed, even
when PRM-A pressure was removed for up to 3 months (Fig 8). In order to identify modifica-
tions in the nucleotide sequence that could be responsible of the changes in mRNA levels, the
sequences of the TbSTT3 gene open reading frames as well as their corresponding 5’UTRs and
3’UTRs were determined as described in supporting information (S8 Fig and S1 Text). Three
nucleotide changes were found in the TbSTT3A coding sequence with regard to the database
sequence resulting in the amino acid changes E510G, K513E and L705P (S1 Table). In the case
of TbSTT3B, a G248S replacement was identifiedwhile no differences were found in TbSTT3C.
Further analysis is currently underway to ascertain the functional significance of the mutations
affecting the TbSTT3 genes. No differences were observed in the sequences of the STT3 UTRs.
Parasites from the parental, PRM-A25, PRM-A50 and PRM-A100-resistant cell lines were
used to infect mice and survivalwas monitored. We observeda strong parasite fitness cost for
the three resistant cell lines that resulted in reduced infectivity. Whereas the parental line exhib-
ited a median survival days (MSD) of 6.0 ± 0.0 days, the four mice infectedwith PRM-A25-re-
sistant parasites and twomice out of the seven infectedwith the PRM-A100-resistant parasites
died showing an MSD of 38 ± 7 days and 34.5 ± 0.7 days, respectively. All the mice infectedwith
PRM-A50 were alive after 50 days (MSD>50 days) (Fig 9). Thus, the PRM-A-resistant parasites
invariably showed a pronounced compromised infectivity potential in mice.
TbSTT3B is involved in resistance to pradimicins
With the aim of establishing if defective expression of OSTs is the major factor involved in resis-
tance to pradimicins, overexpression of TbSTT3A and TbSTT3B in the PRM-A100 cell line and
Fig 8. Relative expression of TbSTT3 genes in PRM-A-resistant trypanosomes. The mRNA levels of
the STT3 genes in the PRM-A100 cell line cultured in the presence or absence of PRM-A and those of the
parental line were determined by RT-qPCR and normalized with regard to the expression of the myosin 1B.
Values were calculated from triplicates of three independent experiments. The asterisks show significant
differences calculated by the Student’s t-test (n = 3). *, p < 0.005, **, p < 0.001 and ***, p < 0.0001 vs the
parental strain.
doi:10.1371/journal.ppat.1005851.g008
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conversely RNAi mediated depletion of TbSTT3A,TbSTT3B and TbSTT3C in the parental line
were accomplished (S1 Text). Firstly, PRM-A100 cells were transfected individually with con-
structs that allowed for the expression of TbSTT3A or TbSTT3B, yielding the PRM-A100
STT3A-OE and PRM-A100 STT3B-OE cell lines, respectively (Fig 10A). The mRNA levels of
the STT3 genes were evaluated by RT-qPCR. TbSTT3BmRNA increased significantly after
induction in the PRM-A100 STT3B-OE cell line, whileTbSTT3AmRNA levels were maximally
1.3-fold enhanced upon induction of PRM-A100 STT3A-OE (Fig 10B). The determination of
EC50 values established that sensitivity to PRM-S in the PRM-A100 STT3B-OE parasites
increased upon induction 12.1-fold with regard to the parent PRM-A100 strain (EC50
77.7 ± 0.8 μM) thus pointing towards a major role for this OST in the resistance mechanism.
Moderate overexpression of TbSTT3A did not result in sensitization to PRM-S, thus curtailing
its role in the resistance phenotype (Table 5). On the other hand, RNAi-mediated depletion of
TbSTT3 genes was evaluated individually or simultaneously in the wild-type strain. Thus, the
cell lines Tb BSF STT3A-RNAi, Tb BSF STT3B-RNAi, Tb BSF STT3A/B-RNAi and Tb BSF
STT3A/B/C-RNAiwere generated.While the knockdown of TbSTT3A or TbSTT3B [5] had no
effect on growth, simultaneous knockdown of TbSTT3A and TbSTT3B or TbSTT3A, TbSTT3B
and TbSTT3C resulted in severe growth defects (Fig 10C and 10E), in agreement with previous
studies showing that N-glycosylation is essential [28] (Fig 10D and 10F). Depletion of TbSTT3B
gave rise to high resistance to PRM-S (14.3-fold) whereas RNAi-mediated reduction of
TbSTT3Ahad no notable consequences and even slightly sensitizes parasites to the drug
(0.6-fold) compared to the parental line (EC50 5.3 ± 0.2 μM) (Table 5). These results confirm the
central role of OSTs in defining the VSG glycosylation profile and PRM-S binding capacity. Spe-
cifically TbSTT3B, which transfers Man9GlcNAc2 rendering oligomannoseN-glycans, appears
as the main player in the molecularmechanism responsible for resistance to pradimicins.
Resistance to PRM-A results in altered endocytosis
To evaluate whether PRM-A resistance involved modifications in endocytosis, PRM-A100-re-
sistant and parental parasite strains were probed with ConA as a marker for membrane-bound
Fig 9. Survival analysis of mice infected with PRM-A-resistant trypanosomes. Kaplan-Meier survival
analysis of mice infected with parental (Tb BSF) and PRM-A25, PRM-A50 and PRM-A100-resistant
parasites.
doi:10.1371/journal.ppat.1005851.g009
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Fig 10. Effect of overexpression or RNAi mediated depletion of STT3A, STT3B and STT3C on resistance to
PRM-S. (A and B) Accumulated growth (A) and mRNA levels (B) of PRM-A100 cells overexpressing TbSTT3A or
TbSTT3B. (C and D) Accumulated growth (C) and mRNA levels (D) of STT3A-RNAi and STT3B-RNAi parental cells.
(E and F) Growth profile (E) and mRNA levels (F) of STT3A/B-RNAi and STT3A/B/C-RNAi parental cells. -DOX,
non-induced; +DOX, cells exposed to doxycycline (1 μg/ml). Relative expression of the STT3 mRNA levels was
determined by RT-qPCR and normalized with regard to the expression of myosin 1B. Values were calculated from
triplicates of two independent experiments. The asterisks show significant differences between induced versus
corresponding non-induced cell lines calculated by the Student’s t-test (n = 2): *, p < 0.05 and **, p < 0.001.
doi:10.1371/journal.ppat.1005851.g010
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endocytic activity [29], transferrin as a receptor-mediated endocytosismarker, and dextran as
a fluid-phase endocytosismarker. PRM-A-resistant parasites exhibit a slightly reduced capacity
to internalize both ConA and transferrin, although internalization was restored when trypano-
somes were cultured in the absence of PRM-A and remain resistant (Fig 11A and 11B). On the
other hand no differences were found in dextran uptake between resistant and parental para-
sites (Fig 11C). Whereas ConA interiorization is dependent on the interaction with surface gly-
cans, transferrin and dextran uptake (fluid phase endocytosis) are mostly independent of
protein glycosylation. Indeedmutant non-glycosylated ESAG6 and ESAG7 (the two subunits
Table 5. EC50 values for PRM-S of PRM-A100 parasites overexpressing TbSTT3A or TbSTT3B, and
wild type parasites subjected to RNAi mediated depletion of TbSTT3A, TbSTT3B and TbSTT3C.
Cell line EC50 non-induced cells (-DOX) (μM) EC50 induced cells (+DOX) (μM)
PRM-A100 STT3A-OE 88.5 ± 6.4 69.7 ± 2.0
PRM-A100 STT3B-OE 71.2 ± 5.9 6.4 ± 1.1
Tb BSF STT3A-RNAi 7.4 ± 0.2 3.4 ± 0.1
Tb BSF STT3B-RNAi 6.75 ± 0.08 75.9 ± 0.2
doi:10.1371/journal.ppat.1005851.t005
Fig 11. Endocytosis analysis. PRM-A100 cells grown both in the presence and absence of PRM-A were used
to evaluate receptor-mediated, receptor independent and fluid-phase endocytosis. The uptake of ConA (A),
transferrin (B) as well as Alexa Fluor 594-dextran 10,000 (C) conjugates were measured and compared with
uptake in the parental line. The asterisks show significant differences calculated by the Student’s t-test (n = 3). *,
p < 0.05, **, p < 0.01 and ***, p < 0.005 vs the parental strain.
doi:10.1371/journal.ppat.1005851.g011
Pradimicins Induce Cure in Animal Models of Sleeping Sickness
PLOS Pathogens | DOI:10.1371/journal.ppat.1005851 September 23, 2016 17 / 30
forming the transferrin receptor) are capable of forming a heterodimer and of binding transfer-
rin [30]. Nonetheless, changes in the glycan nature of the transferrin receptor could interfere
with transferring binding due to steric hindrance.We conclude that the minor reversible
defects observed in ConA and transferrin uptake do not have a major role in the resistance
phenotype.
In vivo PRM-S treatment produces parasitological cure in murine
models of acute sleeping sickness
Given the limited solubility and availability of PRM-A, the trypanocidal effect of several
PRM-A derivatives, including PRM-S, BMS181184 and BMY28864, was examined in mice
using an acute model of African trypanosomiasis.Mice were infected with the T. brucei rhode-
siense EATRO3 ETat1.2 TREU164 or T. brucei brucei single-marker 427 strains. PRM-S exhib-
ited a dosage-related efficacy at intraperitoneal dosages of 25 mg/kg and 50 mg/kg per day
administered on four consecutive days. At 25 mg/kg PRM-S, two of five mice infected with T.
brucei rhodesiense were cured (Fig 12A), and the survivalmarkedly improved for the treated
animals since the MSD was 14.0 ± 3.0 days and the mean relapse days (MRD) 10.7 ± 0.6 days,
while controls treated only with the drug vehicle formulation exhibited a MSD of 7.5 ± 1.7 days
(Table 6). In the case of T. brucei brucei-infectedmice, at 25 mg/kg all the mice died although
the MSD was extended to 18.0 ± 7.0 days with a MRD of 10.7 ± 0.6 days with regard to an
MSD of 6.2 ± 0.5 days in the control (non-treated) group (Fig 12B and Table 6). Notably, at 50
mg/kg, PRM-S produced parasitological cure of all the mice infected with either T. brucei rho-
desiense or T. brucei brucei (Fig 12A and 12B).
Parasites from T. brucei brucei-infectedmice treated with 25 mg/kg PRM-S were isolated
just before animal sacrifice, inoculated into HMI-9 medium and exposed to increasing concen-
tration of PRM-S for determination of the EC50 value. The EC50 obtained (5.0 ± 0.2 μM) was
similar to the control, showing that short term PRM-S exposure in vivo did not generate resis-
tance to PRM-S.
The parasitaemia and morphologywere determined in mice infectedwith T. brucei brucei at
30 min, 1 h and 2 h after drug treatment (50 mg/kg) in order to provide an insight into the
mechanism of action in vivo. PRM-S provokes a rapid parasite clearance (Fig 12C) and a pro-
nounced increase in the population of cells with a rounded shape (90%) (Fig 12D and 12E) sug-
gesting that direct interaction with the parasite surface glycans is the mode of action in the
mouse model.
Other pradimicin derivatives somewhat less active in vitro than PRM-A/PRM-S were also
investigated in vivo. Specifically, BMS181184 and BMY28864 at a single dosage of 50 mg/kg
were used to treat mice infected with T. brucei rhodesiense. BMS181184 produced parasite
clearance after the first dosage yet further relapsed (MRD of 9.0 ± 2.2 days), while the MSD
was extended to 12.8 ± 3.1 days, thereby doubling the survival of the control group (MSD of
6.25 ± 0.5 days). BMY28864-treated animals died at the same time as the control group, and
therefore, proved not to be active in vivo (S9 Fig and Table 6).
Discussion
In this study we have explored the trypanocidal activity of pradimicins and the mode of action
of these non-peptidic CBAs in order to provide an insight into the potential of these highly
novel antiparasitics. Pradimicins are low-molecular-weight antibiotics (~ 900 Da) that exhibit
antiviral and antifungal properties mediated by lectin-mimic binding to surface glycans [11,
12, 14, 17, 31]. We show that these CBAs exhibit a remarkable trypanocidal activity in vitro in
the low micromolar range, in particular PRM-A and its highly water-soluble derivative PRM-S
Pradimicins Induce Cure in Animal Models of Sleeping Sickness
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Fig 12. Treatment of T. brucei- infected mice with PRM-S. (A and B) Kaplan-Meier survival analysis of mice
infected with T. brucei rhodesiense EATRO3 ETat1.2 TREU164 (A) or with T. brucei brucei single-marker strain
427 (B) and treated with 25 mg/kg, and 50 mg/kg of PRM-S as well as with the vehicle used as control. (C)
Parasitaemia course of mice infected with T. brucei brucei single-marker strain 427 at short periods after PRM-S
administration (50 mg/kg). (D) Light microscopy of cells stained with Giemsa from mice infected with T. brucei
brucei at 1 h after PRM-S administration. (E) Quantification of the percentage of cells exhibiting a rounded
shape, which was observed by Giemsa staining. The asterisk shows significant differences calculated by the
Student’s t-test (n = 2). *, p < 0.05, and **, p < 0.005. Bars, 10 μm.
doi:10.1371/journal.ppat.1005851.g012
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proved most active. Extraordinarily, PRM-S also exhibits a potent trypanocidal effect in vivo,
resulting in a parasitological cure in acute models of African trypanosomiasis using both the T.
brucei rhodesiense and T. brucei brucei species. These findings are a continuation of previous
work conducted in our laboratory where we identified a series of plant lectins such as HHA,
UDA, GNA, NPA and EHA, that exhibit strong inhibitory activity against T. brucei [5]. Our
observationswere in contrast to the general belief that most lectins are not toxic for T. brucei
bloodstream forms since rapid internalization and degradation of the surface glycoprotein-lec-
tin complex would result in a lack of toxicity [32]. Although the dissociation constant of the
PRM-A-VSG221 or PRM-S-VSG221 complexes could not be determined in detail due to the
existence of multiple binding sites in the VSG molecule, we provide multiple evidence that the
mode of action of pradimicins is indeed due to tight binding to surface VSGs and perturbation
of the endocytic pathway resulting in a rapid parasite death. Defects in endocytosis of a similar
fashion have been observed earlier upon formation of VSG-specific nanobody complexes
(Nsbs) and have been reported to play an essential role in the nanobody’s cytotoxic action [33].
Studies on the molecularmechanisms of resistance to the pradimicins were designed in
order to shed light on the mode of action of these compounds. Thus resistance was generated by
a step-wise selection to PRM-A and a high resistance index was achieved for mutant cells that
also exhibited cross-resistance to PRM-S and to other mannose-binding lectins. The resulting
resistance phenotype was characterized by defects in theN-glycosylation pathway that resulted
in an alteredN-glycosylation of VSGs and other glycoproteins which presumably lead to a
reduced binding of the CBA. Indeed in the resistant mutant parasites, lectin blotting analysis
together with the observation that CV-N, HHA and UDA uptake and binding are impaired sug-
gested profound modifications in surface glycans. Given that this phenotype remained after
withdrawal of drug pressure, we concluded that the resistance phenotype was genetically
encoded and stable. On the other hand, defects in endocytosis in the resistant mutants were
minor and reversible upon drug withdrawal. Transferrin and ConA uptake reductionwas
reversed after culture in the absence of PRM-A while no defects were observed in fluid-phase
endocytosis thereby establishing that this process is not relevant to the resistance phenotype.
Pradimicins and benanomicins comprise a unique family of antibiotics with a lectin-like
ability to bind D-mannose (D-Man) in the presence of Ca2+ [8, 9, 34]. Lately they have been
attracting attention as the only class of non-peptidic small molecules that can capture D-Man
under physiologically relevant conditions [35]. The evidence available suggests that PRM-A
recognizes the 2-, 3-, and 4-hydroxyl groups of D-Man although binding to pyranosides of l-
Fuc and l-Gal when the Ca2+ concentration is not excessive has also been reported [35]. Both
PRM-A and PRM-S bind HIV-1 gp120 with a dissociation constant (KD) of ~ 0.4 μM and
hence exhibit promising antiviral properties [12]. Here, we demonstrate that pradimicins bind
Table 6. In vivo activities of pradimicin derivatives against T. brucei.
Parasites Mice Drug dose mg/kg days 3–6 route cured/ infected MSD MRD
T. brucei rhodesiense EATRO3 Balb/C - i.p. 0/4 7.5 ± 1.7
PRM-S 4 x 25 i.p. 2/5 14.0 ± 3.0 10.7 ± 0.6
4 x 50 i.p. 5/5 >90
- i.p. 0/4 6.2 ± 0.5
BMS181184 3 x 50 i.p. 0/4 12.8 ± 3.1 9.0 ± 2.2
BMY28864 3 x 50 i.p. 0/4 6.2 ± 0.5
T. brucei brucei 427 SM C57BL/6J - i.p. 0/4 6.2 ± 0.5
PRM-S 4 x 25 i.p. 0/3 18.0 ± 7.0 10.7 ± 0.6
4 x 50 i.p. 6/6 >90
doi:10.1371/journal.ppat.1005851.t006
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primarily to N-glycans of the trypanosome surface glycoproteins. Moreover while PRM-A/S is
able to bind VSGs, affinity is strongly dependent on N-glycan structures and was markedly
reduced in PRM-A-resistant parasites. Moreover, binding competition experiments with HHA
and CV-N indicate clearly that pradimicins compete with these lectins in the interaction with
VSGs. On the other hand, direct evidence for efficient pradimicin binding was provided by
SPR analysis. Indeed, VSGs from resistant parasites exhibit a lower capacity to bind pradimicin
than parental VSGs further confirming changes in glycan composition in order to overcome
the anti-parasitic CBA suppressive effects. Definitive evidence for changes in VSG glycosyla-
tion was obtained by analysis of free and procainamide labelled glycans by mass spectrometry
and liquid chromatography. Mutant resistant cells exhibited a significant reduction in the pro-
portion of oligomannose type glycans, namely H8N2 and H9N2, while hybrid and complex
species accounted for 47% of total glycans versus 23% in the parental cell line. In summary,
studies on VSG endoglycosidase treatment, lectin binding, lectin blotting and glycan composi-
tion show that parasites overcome PRM-A pressure by an alteredN-glycan processing leading
to an enrichment in hybrid and complex N-glycan structures presenting lower numbers of α
(1,2)-mannose residues prone to bind this CBA.
We sought to establish how changes in glycan composition occur in pradimicin-resistant
parasites. It is well-known that VSG glycosylation is accomplished in a site-specificmanner by
the action of two catalytic OSTs: STT3A activity transfers Man5GlcNAc2-PP-Dol to aspara-
gines flanked by an acidic sequence yielding paucimannose structures, and STT3B relocates
Man9GlcNAc2-PP-Dol to any remaining asparagine rendering oligomannoseN-glycans,
respectively [19, 27]. These two enzymes were obvious candidates to be responsible for the
resistance phenotype however there was a possibility that increased trimming of glycans by α
(1,2)-mannosidases is involved. In resistant cells we identified a down-regulation of TbSTT3A
and TbSTT3BmRNA levels that prompts hypoglycosylation and changes in theN-glycan
nature directed towards a reduction of oligomannose and an increase in paucimannose struc-
tures. These modifications clearly minimize their accessibility and the ability for binding pradi-
micins, and consequently are responsible for the appearance of resistance. In this process
TbSTT3B appears to be a major player since overexpression of the enzyme in resistant parasites
reversed resistance to pradimicins while conversely RNAi mediated depletion in wild type par-
asites resulted in high levels of resistance. Thus down-regulation of TbSTTB appears to be the
main mechanism involved in pradimicin resistance. A question that remains to be addressed is
how long term down-regulation of TbSTT3A and TbSTT3BmRNA is achieved. It is well-estab-
lished that trypanosomatids lack the ability to regulate RNA-polymerase II transcription initia-
tion, and the control of mRNA abundance and protein profiles depend largely on RNA-
binding proteins [36]. For example, depletion of DRBD3, an RNA binding protein involved in
mRNA stability, leads to destabilization of several transcripts and splicing defects, binding
preferentially within the 30-UTR of its target genes, although binding sites within the ORFs and
the 50-UTR are possible [37]. We have explored changes in the sequences of 3’ and 5’-UTRs as
well as in the ORFs of STT3 genes as potentially responsible of STT3mRNA down-regulation.
No modifications were identified in the UTRs yet a series of mutations were found in the ORFs
of STT3A and STT3B. The possibility that mutations within the coding region are related with
the modification of mRNA levels has not been established. RNA-binding proteins that bind
within the coding region of mRNAs have been described although their major role is modula-
tion of translation [38]. In addition, the impact of these mutations on the catalytic properties of
OSTs was not examined. Hence, how the expression and function of STT3 genes are regulated
in mutant cells remains to be understood.
The striking efficacy in vivo further demonstrates that we can obtain highly potent and effi-
cient trypanocidalagents by designing compounds that interact with surface glycans. This is an
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entirely novel concept that warrants further investigation. Indeed, our data revealed that small-
size non-peptidic CBAmolecules are emerging as a promising strategy for parasite suppression
although further studies will be required to improve the pharmacokinetic properties of this kind
of compounds and to achieve sufficient central nervous system penetration and efficacy in the late
stage of the disease. Pharmacokinetic data with pradimicin derivatives obtained in previous stud-
ies have shown that drug levels in brain tissue and cerebrospinal fluid were lower than thosemea-
sured in other tissues but detectable at concentrations exceeding 1 μg/g after multiple dosing [39].
Here the trypanocidal activity in vivo appears to result from direct interaction of the CBA
with bloodstream forms since after treatment the morphology of parasites isolated from the
bloodwould suggest a similar mechanism of action to that observed in vitro. Interestingly, an
important consequence of glycosylation changes was the strong fitness cost observed in mice
models. Resistant parasites were either not infective or exhibited a highly attenuated virulence.
These findings are in agreement with previous work that has shown that a correct glycosylation
of VSG is critical for optimal and efficient host-parasite interaction [5, 6, 28].
In conclusion, pradimicins exhibit a highly cytotoxic activity against bloodstream forms of
T. brucei and render parasitological cure in vivo using an acute model of sleeping sickness. By
binding to surface glycans, pradimicins lead to defects in cytokinesis resulting in cell lysis.
While specific binding to surface VSGs has been demonstrated, interaction with other glyco-
proteins cannot be ruled out. All this evidence allows us to propose the development of lectin-




Trypanosoma brucei brucei single-marker bloodstream forms (BSF) (antigenic type 1.2, MITat
1.2, clone 221a) strain 427, harbouring T7 RNA polymerase and the tetracycline repressor [40]
and Trypanosoma brucei rhodesiense EATRO3 ETat1.2 TREU164 [41] were used in this study.
The parasites were cultured at 37°C and 5% CO2 in HMI-9 with 10% (v/v) or 20% fetal bovine
serum, respectively.
Carbohydrate-binding agents
The following non-peptidicmannose-specificCBAs of prokaryotic origin have been used: pra-
dimicin A (PRM-A,Actinomadura hibisca) [7]; pradimicin S (PRM-S,Actinomadura spinosa
strain A A08 51) [42]; pradimicin Fs (PRM-Fs,Actinomadura spinosa strain A A08 51 grown
in presence of D-serine) [14]; pradimicin FA-1 mono sugar (PRM-FA-1 mono sugar, Actino-
madura hibisca P157-2 grown in presence of D-serine) [15]; BMS181184 (synthesized by a
semisynthetic process or by direct production from D-serine supplemented fermentation of
Actinomadura sp) [43]; and BMY28864 (synthesized chemically from PRM-A) [17]. The Ama-
ryllis lectinHippeastrum hybrid agglutinin (HHA) [44], stinging nettle lectin (UDA, Urtica
dioica) [45], broad-leaved helleborine lectin (EHA, Epipactis helleborine) [46], snowdrop lectin
(GNA, Galanthus nivalis) [47], daffodil lectin (NPA, Narcissus pseudonarcissus) [48] and cya-
novirin-N (CV-N, Nostoc ellisporum) [49]. Tomato lectin (TL) and Erythrina cristagally lectin
(ECL) were obtained from Vector Laboratories, Inc and ConA from Sigma.
Generation of PRM-A-resistant cell lines
PRM-A, a non-peptidic CBA with α(1,2) mannose specificity, was used to generate resistant
cell lines of T. brucei bloodstream forms by exposure to increasing concentrations of
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compound. The process started with a pradimicin concentration equal to the EC50
(3.20 ± 0.04 μg/ml) and then stepwise selectionwas performed, obtaining several strains at
escalating PRM-A concentrations of 3.2, 3.6, 10, 25, 50 and 100 μg/ml. Parasites were exposed
to a higher drug concentration when the generation time (6–8 hours) had equalled that of the
parental line, a process which took around 15–25 days. Resistance stability was checked at 1, 2
or 3 months on PRM-A50 and PRM-A100 strains after removal of the drug pressure.
Sequencing and VSG221 expression analysis
The coding sequences for PRM-A50 and PRM-A100 VSG221 were amplified by PCR using
cDNA as template, cloned in the pGEM-T vector (Promega) and finally sequenced.
VSG221 expression was evaluated by immunofluorescence using an anti-VSG221 poly-
clonal antibody on PRM-A-resistant cells as described [5]. Briefly, parasites were fixed for 20
min on poly-L-lysine-coated slides with 4% p-formaldehyde, washed twice (PBS and 0.2%
Tween 20) and blocked during 30 min with Blocking Reagent 1% (Roche). Subsequently, sam-
ples were incubated with anti-VSG221 polyclonal antibody for 1 h, labelled with FITC-conju-
gated anti-rabbit secondary antibody for 1 h, washing before and after labelling. Slides were
then dehydrated in methanol for 1 min and finally stained and mounted with Vectashield-
DAPI (Vector Laboratories, Inc.). The microscopy and digital image acquisition were per-
formed using a Zeiss Axiophot microscope (Carl Zeiss, Inc.)
RNA extraction, cDNA synthesis and real time quantitative PCR (RT-
qPCR)
Total RNA of parental and PRM-A-resistant cell lines was extracted using TRIzol reagent
(Invitrogen), and treated with DNase to avoid a genomic DNA contamination using the
RNeasy Micro kit (Qiagen). cDNA was obtained by reverse transcription using iScript cDNA
synthesis kit (Bio-Rad). Quantitative PCR assays were carried out in an iCycler IQ real-time
PCR detection system (Bio-Rad) using SsoFast EvaGreen Supermix (Bio-Rad). All procedures
were performed according to the manufacturer’s instructions. Relative expression of the
TbSTT3A,TbSTT3B and TbSTT3C genes was measured as described [5] using themyosin 1B
gene (Tb927.11.16310) as reference, which was kindly provided by Dr. Navarro [50]. Three
independent experiments and sample triplicates were performed in all RT-qPCR assays.
Small-scale sVSG (soluble-form VSG) isolation and endoglycosidase
digestion
The sVSG isolation of PRM-A-resistant strains was performed following the protocol
describedby Cross et al [20, 51] with slight modifications. Pellets from 2 x 108 cells were lysed
in 300 μl of hypotonic lysis buffer (10 mM sodium phosphate buffer, pH 8.0 plus protease
inhibitor cocktail (Roche)) for 5 min at 37°C. The supernatant containing VSG was collected
by centrifugation at 14,000 x g for 5 min, loaded onto 0.2 ml of a DE52 (Whatman) and eluated
with 10 mM sodium phosphate buffer, pH 8.0. Finally VSG was diluted in water after concen-
trating and diafiltering on a Nanosep 10K Omega (Pall Corporation).
sVSGs isolated of parental and PRM-A-resistant cell lines were subjected to endoglycosidase
digestion. For each enzyme digestion, 1 μg of sVSG was denatured in 10 μl of 0.5% SDS and 0.1
M dithiothreitol for 10 min at 100°C, followed by overnight treatment at 37°C with 500 units
of Endo H or PNGase F (New England Biolabs) in the corresponding buffer supplied by the
manufacturer.
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Immunofluorescence analysis of VSG expression
To assess the VSG nature in PRM-A-resistant cells, an immunofluorescence analysis using an
anti-TbVSG221 polyclonal antibody was carried out. Trypanosomes were fixed in 4% p-form-
aldehyde on poly-L-lysine-coated slides at RT for 20 min, washed (PBS and 0.2% Tween 20)
and blocked with Blocking Reagent 1% (Roche) for 30 min. Then, samples were incubated with
anti-TbVSG221 for 1 h, washed, probed with FITC-conjugated anti-rabbit antibody for 1 h
and washed again. Slides were finally stained and mounted with Vectashield-DAPI (Vector
Laboratories, Inc.) after dehydrating in methanol. The microscopy and digital image acquisi-
tion were carried out with a Zeiss Axiophot microscope (Carl Zeiss, Inc.)
Surface plasmon resonance (SPR) analysis
Binding of PRM-A and PRM-S to VSG221 expressed in parental or PRM-A-resistant cell lines
was evaluated using SPR on a Biacore T200 instrument (GE Healthcare, Uppsala, Sweden).
TbBSF VSG221 was covalently immobilized on a CM5 sensor chip in 10 mM sodium acetate,
pH 5, using standard amine coupling chemistry, resulting in chip densities of 826 (low-density)
and 6,500 (high-density) RU. The same coupling chemistry was used to immobilize 6,070 RU
of PRM-A100-resistant VSG221 to the sensorchip. Interaction studies with PRM-A were per-
formed at 25°C in HBS-P (10 mMHEPES, 150 mMNaCl and 0.05% surfactant P20, pH 7.4)
containing 5% DMSO and 10 mMCaCl2. Interaction studies with PRM-S were performed in
the same buffer without DMSO (due to a markedly higher solubility of PRM-S versus PRM-A).
A reference flow cell was used as a control for non-specific binding and refractive index
changes. Several buffer blanks were used for double referencing. A variety of PRM-A and
PRM-S concentrations were injected for 2 min at a flow rate of 30 μl/min and followed by a dis-
sociation phase of 5 min. The CM5 sensor chip surface was regenerated with a single injection
of 10 mMNaOH.
HHA-FITC and CV-N-FITC labelling in the presence of PRM-S
An HHA-FITC conjugate binds to VSG N-glycans containing α(1,3) and/or α(1,6) mannose
forming a VSG-HHA complex which is rapidly endocytosed [5]. A CV-N-FITC conjugate
would bind to glycans containing α(1,2) mannose. Competition experiments with HHA-FITC
and CV-N-FITC were used to evaluate binding of PRM-S to VSGs. For this purpose, live
parental T. brucei cells (1.5 x 106 parasites) were washed once with Voorheis PBS (PBS contain-
ing 10 mM glucose and 79 mM sucrose), resuspended in 1 ml of serum-freeHMI-9 medium
containing 1% BSA and preincubated for 20 min at 37°C. Samples were incubated with HHA--
FITC (1 μg/ml) or CV-N-FITC (0.6 μg/ml) in the presence or absence of PRM-S, washed twice
with cold PBS and resuspended finally in PBS. FACS analysis was carried out using a Becton
Dickinson FACSCalibur and BD CellQuest Pro version 4.0.2 software. For microscopy analy-
sis, cells were fixed after labelling with 2% p-formaldehyde for 1 h at 4°C, washed, adhered on
poly-L-lysine coated slides, dehydrated in methanol and stained with Vectashield-DAPI (Vec-
tor Laboratories, Inc.). Vertical stacks of 10–15 slices (0.2 μm steps) were captured using an
Olympus microscope and Cell R IX81 software. Deconvolution and pseudo-colouringof
images was performed using Huygens Essential software (version 3.3; ScientificVolume Imag-
ing) and Image J software (version 1.37; National Institutes of Health), respectively.
Labelling assays
UDA-FITC conjugates that bind to N-acetylglucosamine residues of VSG N-glycans [6],
CV-N-FITC and HHA-FITC were used to establish changes in glycan nature. Samples of live
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parental and resistant T. brucei cells were prepared and labelled using CV-N-FITC (0.6 μg/ml),
HHA-FITC (1 μg/ml) and UDA-FITC (5 μg/ml).
Uptake assays
Endocytosis dynamics in the parental line upon PRM-S supplementation and in the presence
or absence of HHA (1 μg/ml) was determined by uptake of Alexa Fluor 488-dextran 10,000
conjugates (1 mg/ml) in 50 μl of final sample volume. To analyse endocytosis in PRM-A-resis-
tant cell lines, AlexaFluor 594-ConA (100 μg/ml), FITC-transferrin (50 μg/ml), and Alexa
Fluor 594-dextran 10,000 (1 mg/ml) conjugates were used as described [5]. All conjugates were
purchased fromMolecular Probes Inc (Life technologies, Thermo Fisher Scientific Inc). Sam-
ples were prepared and analysed as described above for FACS analysis.
Lectin blotting
In order to study the glycosylation profile of the PRM-A-resistant strains, lectin blotting using
TL, ECL and ConAwas performed. Both, sVSG (2 μg) and cell pellets (1 x 10−6 cell equivalents/
sample) coming from hypotonic lysis of PRM-A100 cells were denatured in SDS-sample buffer
containing 8 M urea and 50 mMDTT, analysed usingMOPS electrophoresis on NuPAGE Bis-
Tris 4–12% gradient gel (Invitrogen) and transferred to a nitrocellulosemembrane. Proteins
were stained with Ponceau S (Sigma) as loading control and blockedwith 3% BSA in PBS, previ-
ously probing with either biotinylated TL (0.33 μg/ml, Vector Laboratories, Inc.) in a solution
containing 50 mMTris-HCl pH 7.4, 0.5 M NaCl, 0.05% IGEPAL and 0.25% BSA, biotinylated
ECL (1 μg/ml, Vector Laboratories, Inc.) in a solution containing 10 mMHEPES pH 7.4, 0.15
MNaCl, 1 mMCaCl2, 0.05% IGEPAL and 0.25% BSA, or biotinylated ConA (0.05 μg/ml,
Sigma) in PBS containing 1 mMMgCl2, 1 mMCaCl2, 1 mMMnCl2, 0.05% IGEPAL and 0.25%
BSA. In all cases, specific inhibitors of lectin binding such as chitin hydrolysate (1:10 dilution,
Vector Laboratories, Inc.) for TL, D-lactose (0.2 M, Sigma) for ECL and methyl α-D- manno-
pyranoside (0.5 M, Sigma) for ConAwere used as carbohydrate-specific binding controls.
Finally, glycoproteins were detectedwith Extravidin-peroxidase conjugated (Sigma) by chemilu-
minescent detection ECLWestern Blotting DetectionReagents (GE Healthcare).
T. brucei VSG221 N-glycan analysis
Glycan profiling by mass spectrometry and liquid chromatography was performed to gain a
more detailed view of VSG glycosylation including the relative quantification of glycan distribu-
tion. T. bruceiVSG221 samples (50 μg) of parental (Tb BSF) and resistant (PRM-A100) cells
were denatured and enzymatically deglycosylatedwith PNGase F according to the manufac-
turer´s instructions (New England Biolabs, PNGaseF glycerol free). After deglycosylation, the
protein fractionwas removed by filtration on a 10 kDa spin filter (Amicon Ultra-0.5 ml Centrif-
ugal Filters, Merck Millipore), recovering the free glycans in the filtrate. The released glycans
from 50 μg of VSG221 protein were purified over C18 loaded Zip-Tips to remove polymers, the
sample was treated with 1 μl of sodium citrate tribasic (1 mM) to favour the exclusive produc-
tion of sodium adducts and subjected to MALDI-TOFMS analysis. Super-DHB was used as
MALDImatrix as a 20 mg/ml solution in ACN. 1 μl of both sample and matrix solution were
spotted to the MALDI sample plate into the same spot. The spectra were recorded in reflector
positive mode in the 700–3000 Da range, on an UltrafleXtreme III MALDI-TOF, Bruker Dal-
tonics, Germany. Further information on glycan structure was obtained by fragmentation by
MALDI-TOFMS selecting the ions 2393 m/z, 2028 m/z and 1663 m/z, and employing in-source
fragmentation routine (LIFT, Bruker). Glycan fragments were identified using the Flexcontrol
Ultraflex TOF/TOF software application and GlycoWorkBench 2.1 free software.
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A relative quantification of the glycan profile was performed by analysing procainamide
labelled glycans by UPLC-FLD-MS. Glycans were enzymatically released from 50 μg of filtered
VSG221, dried and labelled with procainamide (procainamide/cyanoborohydride in DMSO/
AcOH) for 3h at 60°C. The labelled glycans were dried, redissolved in ACN, and analysed by
UPLC-FLD on an Acquity UPLC Glycan BEH amide column (1.7 μm, 2.1 mm x 150 mm) in
ammonium formate/ACN. Fluorescent labelled glycans were detectedwith a FLD and an ESI--
TOF mass analyser.
In vivo studies
PRM-S, a more soluble analogue of PRM-A, BMS181184 and BMY28864, were used to evalu-
ate the trypanocidal activity in vivo of CBAs. Groups containing between three to six C57BL/6
or Balb/Cmice (6–8 weeks old) (Jackson Laboratories, Bar Harbor, ME) were infected intra-
peritoneally with 5 x 103 monomorphic T. brucei brucei (PRM-S treatment) or 1 x 104 T. brucei
rhodesiense parasites (PRM-S, BMS181184 and BMY28864 treatment), respectively. Different
dosages of 25 mg/kg and 50 mg/kg of PRM-S (four dosages) and 50 mg/kg of BMS181184 and
BMY28864 (three dosages), were administered once a day intraperitoneally (0.2 ml) starting
on the third day post-infection.Compounds were initially dissolved in PBS at 12.5 mg/ml, fol-
lowed by dilution in 0.5% w/v hydroxypropylmethylcellulose, 0.4% v/v Tween 80 and 0.5% v/v
benzyl alcohol used as dosage formulation. One group of mice in each case was also infected
and treated with the vehicle as control. Parasitaemia was monitored daily in a haematocyt-
ometer and morphologywas examined under a microscope from the third day post-infection
and after tail blood extraction.
To study the effect of the glycosylation changes observed in PRM-A-resistant parasites on
infectivity, 600 monomorphic T. brucei brucei parasites of parental, PRM-A25, PRM-A50 and
PRM-A100 strains were used to infect intraperitoneally between four and seven female C57BL/6
mice per group, respectively (6–8 weeks old). Parasitaemia was monitored daily in a haematocyt-
ometer under a microscope from the fourth day post-infection and after tail blood extraction.
Ethics statement
The animal research described in this manuscript complied with Spanish (Ley 32/2007) and
European Union Legislation (2010/ 63/UE). The protocols used were denoted as 1646/13
(PRM-A100 infection), 511/15.2 (PRM-A25 and PRM-A50 infection), 1947/13.A.1, 1947/13.
B.1 and DGP.2/2014/CEEA (PRM-S treatment) and 2738/13.A.1 (BMS181184 and BMY28864
treatment) and approved by the Animal Care Committee of the Instituto de Parasitología y
Biomedicina “López-Neyra”, CSIC.
Statistical analysis
We expressed the results as the mean ± SD for each group, and comparisons between groups
were performed using Student’s t-tests using a commercially available, computer-based statisti-
cal package (GraphPad Software Inc.) for all calculations. A p value0.05 was considered sta-
tistically significant.
Supporting Information
S1 Fig. EC50 determination.Growth inhibition profile of T. brucei brucei single-marker strain
427 bloodstream forms treated with different pradimicin derivatives. Cells were cultured in
triplicate for 48 hours with varying concentrations of pradimicins.
(TIF)
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S2 Fig. Alignment of the VSG221 sequences from parental and PRM-A-resistant cell lines.
The alignment was obtained with ClustalW2 (EMBL-EBI).
(TIF)
S3 Fig. MALDI-TOF spectraof VSG221 N-glycans of parental (Tb BSF) and PRM-A100-re-
sistant cell lines.
(TIF)
S4 Fig. MALDI-TOF fragmentation spectra (LIFT) of H7N6 glycans of the PRM-A100-re-
sistant cell line.
(TIF)
S5 Fig. MALDI-TOF fragmentation spectra (LIFT) of H6N5 glycans of the PRM-A100-re-
sistant cell line.
(TIF)
S6 Fig. MALDI-TOF fragmentation spectra (LIFT) of H5N4 glycans of the PRM-A100-re-
sistant cell line.
(TIF)
S7 Fig. PCR analysis of the TbSTT3 genes using genomic DNA as template. (A) Scheme of
TbSTT3 genes and the likely rearrangements betweenTbSTT3B and TbSTT3C genes, which
were observed in an HHA20-resistant cell line and reported previously [5]. Name of the prim-
ers used in the study are included in the scheme. (B) PCR product analysis of the full-length
and chimeric TbSTT3 genes according to the scheme shown in panel A in both PRM-A50 and
PRM-A100 resistant strains.
(TIF)
S8 Fig. Sequencing of the ORFs and UTRs of the TbSTT3 genes. Scheme of the DNA region
containing the TbSTT3 genes. Sequencingwas performed on DNA purified from agarose gels
after restriction endonuclease digestion using different primers.
(TIF)
S9 Fig. BMY28864 and BMS181184-treatment of Balb/Cmice infectedwith T. brucei rho-
desienseEATRO3 ETat1.2 TREU164. (A and B) Parasitaemia of animals treated with 50 mg/
kg of BMY28864 (A) BMS181184 (B) and the vehicle used as control. (C) Kaplan-Meier sur-
vival analysis of mice infected and treated. † denotes the day of infectionwhenmice died.
(TIF)
S1 Table. Oligosaccharyltransferaseamino acid changes encodedby the TbSTT3A,
TbSTT3B and TbSTT3C genes in PRM-A100-resistant cells compared to the parental cell
line.
(DOCX)
S1 Text. Text describes the methodologyused to perform the plasmid constructs and trans-
fection, as well as the DNA sequencing strategy for oligosaccharyltransferase genes.
(DOCX)
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